ArticleJournal of viral hepatitis2025
Characterisation of People Living With Chronic Hepatitis B Virus Infection in England and Stratification by HBsAg Levels: A Cross-Sectional Study.
Article in Journal of viral hepatitis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Characterisation of People Living With Chronic Hepatitis B Virus Infection in England and Stratification by HBsAg Levels: A Cross-Sectional Study.Journal of viral hepatitis · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
Abstract
Characterisation of people with hepatitis B (PwHB) remains limited, particularly regarding treatment status, disease severity and biomarker profiles. Quantitative hepatitis B surface antigen (qHBsAg) is a key predictor of response to emerging therapies, but its distribution is poorly described. Using a large, ethnically diverse UK cohort, we assessed demographics, clinical features and HBsAg levels to guide treatment strategies. This cross-sectional analysis of PwHB (N = 2000 [prespecified]) used data from four English hospitals, collected via the National Institute for Health and Care Research Health Informatics Collaborative framework. Individual characteristics were assessed overall, and post hoc by qHBsAg levels (≤ 3000/> 3000 IU/mL; < 100/≥ 100-≤ 1000/> 1000 IU/mL) available from one centre (N = 457). The cohort had a slight male predominance (54%) and a mean age of 44.9 years. White and Asian ethnicity each accounted for 25%, and 23% were on nucleos(t)ide analogue therapy. Centres collecting HBsAg data had more individuals with undetectable HBV DNA or on treatment. Among individuals with non-missing qHBsAg data (263/457), 167/263 (63.5%) had qHBsAg ≤ 3000 IU/mL. These were older (49.6 vs. 43.5 years), more likely to be male (53.9% vs. 35.4%), Asian (40.7% vs. 20.8%) or have undetectable HBV DNA (35.9% vs. 17.7%), and less likely to be Black (13.2% vs. 34.4%) versus those with qHBsAg > 3000 IU/mL. Fifty-six (21.3%) people had qHBsAg < 100 IU/mL, 60 (22.8%) between ≥ 100 and ≤ 1000 IU/mL, and 147 (55.9%) > 1000 IU/mL. This cohort of PwHB highlights qHBsAg distribution in clinical settings and could identify people more likely to achieve functional cure with emerging therapies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.